The content published in Cureus is the result of clinical experience and/or research by independent individuals or organizations. Cureus is not responsible for the scientific accuracy or reliability of data or conclusions published herein. All content published within Cureus is intended only for educational, research and reference purposes. Additionally, articles published within Cureus should not be deemed a suitable substitute for the advice of a qualified health care professional. Do not disregard or avoid professional medical advice due to content published within Cureus.

Introduction
============

The 2019 national outbreak of e-cigarette, or vaping, product use-associated lung injury (EVALI) reported by 25 state health departments included hundreds of reported cases. By January 2020, over 2000 cases had been reported to the Centers for Disease Control and Prevention (CDC) \[[@REF1]\]. The epidemic set the stage for the CDC to release interim recommendations to health care providers to recognize and manage respiratory problems arising from electronic nicotine delivery systems (ENDS) \[[@REF2],[@REF3]\]. ENDS comprises electronic cigarettes, pipes, vaporizers, cigars, and numerous other products. EVALI is an umbrella term incorporating a spectrum of respiratory illnesses ranging from mild cases of pneumonitis to life-threatening lung failure with the most extensive case series reporting 32% of patients requiring intubation and mechanical ventilation \[[@REF4]\]. Reported trends reveal 80% of users to be between 13 to 85 years of age, while most users were male \[[@REF2],[@REF3]\]. Analysis of these products has not revealed any evidence of tainting with microbes, and the constellation of symptoms seems to be more in line with acute lung injury \[[@REF5]\]. The use of electronic cigarettes or the equivalent within the past 90 days continues to be the primary risk factor. A review of the literature reveals various types of injuries from the use of ENDS, such as explosion injuries, dermal reactions, while the most common remains the development of respiratory symptoms. Despite substantial reductions in usage, incidence rates have continued to progress, placing precedence on continued surveillance and public outreach efforts. Although advancements in researching e-cigarettes have grown, its instantaneous and prolonged influences on health remain unclear. Reports focusing on symptom timelines are scarce, ranging as early as few days after initial use to the development of symptoms after months or years of chronic smoking. We present a case of acute lung injury that manifested within hours of first-time e-cigarette use. This report focuses on the duration and timeline of symptom development with an emphasis on acute lung injuries that manifested within one month of ENDS product use.

Case presentation
=================

A 41-year-old man presented to an urgent care facility with an unrelenting cough and shortness of breath that began after multiple uses of an e-cigarette within the span of a few hours. He had been a daily cigarette smoker for 11 years, had never used electronic methods of smoking before and decided to transition to e-cigarettes with the plan to eventually quit smoking. He had acquired the unlicensed product from a friend, with the primary ingredient being a nicotine-based oil. He was diagnosed with tracheobronchitis after a negative chest radiograph, and was given a five-day course of azithromycin and requested to follow up with his primary care physician (PCP). Despite the antibiotic, his symptoms evolved over the next 48 hours to nausea, vomiting, pleuritic chest and abdominal pain, non-productive cough, and worsening shortness of breath, prompting him to go to the emergency department (ED). He denied having been diagnosed with any medical conditions, including symptoms consistent with episodes of bronchitis, pneumonia, or an admission that required supplemental oxygen in the past. He denied experiencing similar symptoms or adverse reactions to smoking in the past, nor did he have occupational or domestic inhalation exposures, recent travel, or exposures to sick contacts. On admission, blood pressure was 186/108, heart rate was 141, O2 saturation was 98% on room air, tachypneic to 23, and afebrile. On exam, he appeared ill, coughing and was writhing in pain, while the remaining exam was unremarkable. He was given ketorolac for analgesia and 0.1 mg of clonidine for his elevated blood pressure. Empiric azithromycin 500 mg and ceftriaxone 2000 mg were given for community-acquired pneumonia (CAP). Interspersed were albuterol 2.5 mg and ipratropium 0.02% nebulization treatments every four hours for his symptoms.

His initial complaint of chest pain prompted an ECG and troponin testing that were unremarkable. Complete blood count was notable for neutrophilic leukocytosis of 12.1 K/UL, while serum chemistries were unremarkable. Antero-posterior and lateral chest X-rays were unremarkable (Figures [1](#FIG1){ref-type="fig"}, [2](#FIG2){ref-type="fig"}). However, his persistent tachypnea and shortness of breath with a moderate pretest probability prompted a computed tomography (CT) angiogram suspecting pulmonary embolism (PE). Imaging revealed parenchymal changes consistent with bilateral upper and lower lobe ground-glass opacities (Figures [3](#FIG3){ref-type="fig"}-[5](#FIG5){ref-type="fig"}). No septal change was noted, helping us rule out causes such as organizing pneumonia, lipoid pneumonia, and diffuse alveolar damage. Extensive testing for viral and bacterial infections was all negative (Table [1](#TAB1){ref-type="table"}). During his stay, he remained hemodynamically stable with an oxygen saturation above 92%, and his pain had improved. Bronchoalveolar lavage (BAL) testing was not considered due to the rapidity of clinical improvement. He was switched to levofloxacin 750 mg daily towards a full CAP course and recommended over the counter ibuprofen for his sore chest. At his two-week visit, he endorsed giving up e-cigarettes but had resumed traditional cigarette smoking, and denied experiencing any further soreness or pain.

![An unremarkable anteroposterior chest radiograph on admission](cureus-0012-00000007513-i01){#FIG1}

![An unremarkable lateral chest radiograph on admission](cureus-0012-00000007513-i02){#FIG2}

![A computed tomography (CT) of the chest with bilateral ground-glass opacities (black arrows)](cureus-0012-00000007513-i03){#FIG3}

![A computed tomography (CT) of the chest with bilateral ground-glass opacities seen with involvement of the posterior parenchyma (black arrows)](cureus-0012-00000007513-i04){#FIG4}

![A lateral computed tomography (CT) of the chest revealing changes consistent with ground-glass opacities](cureus-0012-00000007513-i05){#FIG5}

###### Laboratory investigations during electronic, or vaping, product use-associated lung injury (EVALI)

  --------------------------------------------------------- ---------------------------------------------------
  Laboratory investigation                                  Value
  Sodium                                                    133 meq/L
  Potassium                                                 4.0 meq/L
  Magnesium                                                 1.4 mg/dL
  Creatinine                                                0.7 mg/dL
  Anion Gap                                                 8 meq/L
  White Blood Cell Count                                    12.1 K/uL
  Hemoglobin                                                13.4 g/dL
  Platelet Count                                            269 K/uL
  Neutrophil                                                83%
  Lymphocyte                                                10%
  Routine HIV Ag/Ab 4^th^ Generation                        Negative
  Hepatitis B Surface Antigen                               Negative
  Hepatitis B Surface Antibody                              Negative
  Hepatitis C Antibody                                      Negative
  Toxicology Screen                                         Positive for Opiates & Tetrahydrocannabinol (THC)
  Troponin I                                                \<0.01 ng/ml
  Urine Legionella antigen                                  Negative
  Adenovirus                                                Negative
  Coronavirus 229E                                          Negative
  Coronavirus HKU1                                          Negative
  Coronavirus NL63                                          Negative
  Coronavirus OC43                                          Negative
  Human metapneumovirus                                     Negative
  Human Enterovirus/Rhinovirus                              Negative
  Influenza A                                               Negative
  Influenza B                                               Negative
  Parainfluenza Virus (PIV) 1                               Negative
  Parainfluenza Virus (PIV) 2                               Negative
  Parainfluenza Virus (PIV) 3                               Negative
  Parainfluenza Virus (PIV) 4                               Negative
  Respiratory Syncytial Virus                               Negative
  Bordetella parapertussis                                  Negative
  Bordetella pertussis by Polymerase Chain Reaction (PCR)   Negative
  Chlamydia Pneumonia                                       Negative
  Mycoplasma Pneumonia                                      Negative
  Streptococcus Pneumonia antigen                           Negative
  Sputum cultures                                           No growth
  --------------------------------------------------------- ---------------------------------------------------

Discussion
==========

We present a case of acute lung injury using the EVALI diagnostic criteria recently proposed by the CDC \[[@REF2],[@REF3]\]. Although the exact pathogenesis of EVALI is unknown, a recent analysis of 29 bronchoalveolar lavages (BAL) revealed vitamin E acetate in all the samples, making it the first concerning ingredient in these injuries \[[@REF6]\]. Similarly, in a follow-up study of 51 BAL samples collected across the country, 94% of the non-healthy samples contained vitamin E acetate. Among other additives, tetrahydrocannabinol (THC) was noted in 75 to 90 percent of the samples, while isolated nicotine was observed in 13-58 percent \[[@REF2],[@REF3]\]. One coordinated public health effort found 94% of patients using an ENDS product in the week preceding their exacerbation, demonstrating a crucial modifiable risk factor \[[@REF5]\]. In a patient with product use, respiratory symptoms, a negative chest radiograph, and clinical suspicion of lung injury, a CT scan of the chest can provide diagnostic value \[[@REF7]\]. Consider admission for patients with respiratory distress, O2 saturation below 95% on room air, or concern for lung injury from e-cigarettes used within the preceding 90 days, while many EVALI patients have had persistent hypoxemia requiring home oxygen and bronchodilators at discharge, long-term effects are unknown, and follow-up is strongly advised \[[@REF3],[@REF8]\]. Despite the scarcity of reported short- and long-term adverse effects from these products, animal and observational studies and a few clinical trials have tried to fill this gap, finding numerous adverse effects from these products. Conditions such as hypersensitivity pneumonitis, lipoid pneumonia, and eosinophilic pneumonia have demonstrated oxidative stress, protease concentrations, and alveolar changes similar to the lungs of a traditional tobacco smoker \[[@REF9]\].

The National Academies of Sciences, Engineering, and Medicine (NASEM), based on studies of various compounds found in these products, released statements to address the myths of ENDS \[[@REF10]\]. It reported limited evidence for improvement in lung function and respiratory symptoms in adults who switched to e-cigarettes, and a more robust recommendation that ENDS does have respiratory effects and can increase coughing and wheezing, and possibly exacerbate underlying asthma \[[@REF10]\]. Inhaled nicotine is linked to chronic airway disease and lung remodeling from phenotypic studies based on levels of cytotoxic damage from increased mitochondrial reactive oxygen species seen after aerosol exposure of nanoparticles leading to an unstable electron transport chain and nuclear DNA disintegration \[[@REF11],[@REF12]\]. The most extensive case series of patients accrued from the Illinois and Wisconsin departments of health demonstrated a variety of symptomatology, with 98% of the patients presenting with respiratory symptoms, 81% with gastrointestinal symptoms, and almost all having constitutional symptoms. Imaging revealed bilateral infiltrates in all cases, while 94% of patients were hospitalized, and 32% required intubation and mechanical ventilation. Despite popular belief, a meta-analysis reviewing trends among smokers and ever smokers demonstrated that the probability of using e-cigarettes was much more significant in current smokers than ever smokers. At the same time, a subgroup analysis revealed that ever e-cigarette use was more commonly seen within adolescent smokers \[[@REF13]\].

EVALI is a diagnosis of exclusion, and numerous other causes must be ruled out in the process of confirmation. However, the most critical risk factor remains e-cigarette or vaping use in the 90 days preceding symptom onset. Confirmed cases often include findings of opacities on chest radiography or CT and the absence of pulmonary infections, including viral and bacterial pathogens. Sputum cultures can be obtained while HIV testing for opportunistic infections should be completed as well \[[@REF2]\]. A thorough literature review revealed multiple cases of EVALI with varying durations of product use before symptom development, ranging from a few hours to months. We consolidated cases where the reported duration was less than one month of product use in Table [2](#TAB2){ref-type="table"}, while cases with unknown duration, or beyond one month were excluded. Our goal was to parse out cases with rapid onset, although this does not represent an exhaustive list. The importance of our case stems from its acute presentation and the possibility that e-cigarettes may pose a higher risk in existing smokers, as seen in our patient who never had any symptoms until the e-cigarette use. Our patient developed symptoms of chest and abdominal pain immediately after using the product for the first time. Only one other case reports such quick onset of symptoms, although not during the first time of use \[[@REF14]\]. EVALI has far-reaching consequences, and avoidance of all products is paramount, in contrast, follow-up is crucial, as many can continue to experience respiratory symptoms with continued dependence on supplemental oxygen.

###### Overview of reported respiratory cases from e-cigarette or vaping use less that fall under the electronic, or vaping-associated lung injury (EVALI) spectrum with duration of product use less than one month

  -------------------------------- ----------------- -------------------------------------------- -------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------
  Author                           Number of cases   Duration of product use prior to diagnosis   Diagnosis                                                      Chest X-ray                                                                                              Chest CT                                                                                                     Bronchoalveolar lavage
  He et al. \[[@REF14]\]           1                 6 hours                                      Severe acute lung injury                                       Not done                                                                                                 Extensive airspace opacification in a centrilobular nodular pattern                                          Hemorrhagic return
  Hureaux et al. \[[@REF15]\]      1                 One week                                     Subacute bronchial toxicity                                    Unchanged                                                                                                Not done                                                                                                     Not done
  Thota and Latham \[[@REF16]\]    1                 3 days                                       Acute eosinophilic pneumonitis                                 Subtle diffuse patchy reticulonodular opacities                                                          Diffuse ground glass opacities involving the upper and middle lobes of the lungs more than the lower lobes   White blood cells with eosinophilia
  Moore et al. \[[@REF17]\]        1                 3 days                                       Acute bilateral pneumonia with bilateral pulmonary effusions   Bilateral hypo inflated lungs with bibasilar parenchymal consolidation and bilateral pleural effusions   Unremarkable                                                                                                 Not done
  Mantilla et al. \[[@REF18]\]     1                 4 weeks                                      Bronchiolitis obliterans organizing pneumonia                  Unknown                                                                                                  Bilateral multiple small pulmonary nodules                                                                   Unknown
  Long et al. \[[@REF19]\]         1                 4 weeks                                      Inhalation injury leading to diffuse alveolar hemorrhage       Bilateral diffuse lung infiltrates                                                                       Bilateral diffuse lung infiltrates                                                                           Hemorrhagic return
  Sommerfeld et al. \[[@REF20]\]   1                 2-3 weeks                                                                                                   Patchy bilateral pulmonary infiltrates                                                                   Bilateral opacities, interlobular septal thickening and bilateral pleural effusions                          cellular debris and reactive mononuclear cells, and cell counts were remarkable for elevated mononuclear cells and eosinophilia
  -------------------------------- ----------------- -------------------------------------------- -------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------

Conclusions
===========

E-cigarette, or vaping product use-associated lung injury (EVALI) is a spectrum of respiratory manifestations, with the most critical risk factor being e-cigarette or vaping in the 90 days preceding symptom onset. It is a diagnosis of exclusion requiring imaging modalities demonstrating bilateral changes, ruling out of viral, bacterial, and atypical pathogens and other pulmonary pathologies. The most common adulterants identified in samples are vitamin E acetate, THC, and nicotine. Symptoms may develop as early as a few hours after inhalation to months after use. Follow-up care is vital to demonstrate the resolution of symptoms and radiographic findings. The Centers for Disease Control and Prevention have released interim guidelines to identify and manage cases of EVALI. At the same time, more research is required to parse out the pathophysiology and mechanism behind lung injury and the instantaneous effects that these devices pose while long-term studies are essential.
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